Wize begins enrollment in phase 4 study of LO2A for dry eye in patients with Sjögren’s syndrome

A phase 4 clinical trial of LO2A for the symptomatic treatment of dry eye syndrome in patients with Sjögren’s syndrome has enrolled its first patient in Israel, according to a press release from Wize Pharma.
The randomized, double-masked study will include 60 patients with Sjögren’s syndrome. One group of patients will receive LO2A and the other will receive Systane Ultra UD (Alcon) over-the-counter lubricant eye drops over 3 months.
The study’s primary endpoint is change in corneal/conjunctival staining score after 3 months, and secondary endpoints are

Full Story →